Download PDF
Geburtshilfe Frauenheilkd 2007; 67(6): 595-601
DOI: 10.1055/s-2007-965289
Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Development of Endocrine Therapy of Breast Cancer 1896 - 2006

Entwicklung der endokrinen Therapie des Mammakarzinoms 1896 - 2006A. Howell1
  • 1CRUK Department of Medical Oncology, University of Manchester, UK
Further Information

Publication History

received 15.12.2006 revised 23.4.2007

accepted 26.4.2007

Publication Date:
04 July 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Obwohl die Vorstellung, dass die Mamma durch die Hormone der Ovarien beeinflusst wird, noch wesentlich älter ist, wurden die ersten klinischen Experimente zur Ovarektomie, die zur Regression eines Mammakarzinoms führten, 1896 veröffentlicht. Seit dieser Zeit sind bei prämenopausalen Frauen die Suppression der Ovarialfunktion und bei postmenopausalen Frauen die Aromatasehemmer eine Standardbehandlung zur Reduktion der Östrogenspiegel geworden. Ein anderer entscheidender Ansatz der endokrinen Therapie ist die Blockierung des Östrogenrezeptors mit hohen Dosen Östrogen, erstmals berichtet im Jahr 1944, und der Einsatz von selektiven Östrogenrezeptormodulatoren oder reiner Antagonisten wie Tamoxifen und Fulvestrant. Die Entwickung dieser Pfeiler der endokrinen Therapie wurde vor allem im Europa geleistet und die German Adjuvant Breast Cancer Group (GABG) ist hier seit Jahren in der ersten Reihe.

Abstract

Although the idea that the breast could be influenced by hormones from the ovaries was older, the first clinical experiment of oophorectomy resulting in regression of breast cancer in women was published in 1896. Since that time ovarian suppression has become a standard method of treatment for reducing estrogen concentrations in premenopausal women and aromatase inhibitors for postmenopausal women. The other major approach to endocrine therapy is to block the estrogen receptor with high dose estrogen first reported in 1944 and selective estrogen receptor modulators and downregulators such as tamoxifen and fulvestrant. The development of the two pillars of endocrine therapy estrogen reduction and receptor blockade has occurred particularly in Europe and the German Adjuvant Breast cancer Group has been at the forefront of these developments for many years.

Schlüsselwörter

Tamoxifen - Fulvestrant - Aromataseinhibitor - SERM

Key words

Tamoxifen - Fulvestrant - aromatase inhibitor - SERM

References

  • 1 Ahmed S R, Brooman P J, Shalet S M, Howell A, Blacklock N J, Rickards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.  Lancet. 1983;  2 415-419
    PubMedGoogle Scholar
  • 2 Allen E, Doisy E A. An ovarian hormone: preliminary report on its localisation, extraction and partial purification and action in test animals.  J AmerMed Assoc. 1923;  81 819-821
    PubMedGoogle Scholar
  • 3 Allen J M, O'Shea J P, Mashiter K, Williams G, Bloom S R. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.  Br Med J (Clin Res Ed). 1983;  286 1607-1609
    PubMedGoogle Scholar
  • 4 Anbazhagan R, Bartkova J, Nathan B, Gusterson B A. Extramedullary haematopoiesis in the human infant breast.  The Breast. 1992;  1 182-186
    CrossrefPubMedGoogle Scholar
  • 5 Ascheim S, Zondek B. Hypophysenvorderlappenhormon und Ovarialhormone im Harn von Schwangeren.  Klin Wochenschr. 1927;  6 1322
    PubMedGoogle Scholar
  • 6 Bachmann W E, Cole W, Wilde A L. The total synthesis of the sex hormone equilenin.  J Amer Chem Soc. 1939;  61 974
    PubMedGoogle Scholar
  • 7 Baum M, Brinkley D M, Dossett J A, McPherson K, Patterson J S, Rubens R D, Smiddy F G, Stoll B A, Wilson A, Lea J C. et al . Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.  Lancet. 1983;  2 450
    PubMedGoogle Scholar
  • 8 Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.  Lancet. 1896;  ii 104-107
    PubMedGoogle Scholar
  • 9 Bishop H. Sir George Beatson (1848 - 1933).  The Breast. 1992;  1 179-181
    CrossrefPubMedGoogle Scholar
  • 10 Bonneterre J, Buzdar A, Nabholtz J M, Robertson J F, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M. Arimidex Writing Committee . Anastrozole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast cancinoma.  Cancer. 2001;  92 2247-2258
    CrossrefPubMedGoogle Scholar
  • 11 Burrows H. Carcinoma mammae occuring in the male mouse under continued treatment with oestrin.  Amer J Cancer. 1935;  24 613
    PubMedGoogle Scholar
  • 12 Buzdar A U, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer.  Oncology. 1988;  45 344-345
    CrossrefPubMedGoogle Scholar
  • 13 Clarke M J. Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review.  BMJ. 1998;  317 1246-1248
    PubMedGoogle Scholar
  • 14 Coates A S, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Castiglione-Gertsch M, Gelber R D. et al . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.  J Clin Oncol. 2007;  25 486-492
    CrossrefPubMedGoogle Scholar
  • 15 Cole M P, Jones C TA, Todd I DH. A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI 146474.  Brit Journal of Ca. 1971;  25 270-275
    CrossrefPubMedGoogle Scholar
  • 16 Coombes R C, Goss P, Dowsett M, Gazet J-C, Brodie A. 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.  Lancet. 1984;  11 1237-1239
    PubMedGoogle Scholar
  • 17 Coombes R C, Hall E, Gibson L J, Paridaens R, Jassem J, Delozier T, Jones S E, Alvarez I, Bertelli G, Ortmann O. et al . A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.  N Eng J Med. 2004;  350 1081-1092
    CrossrefPubMedGoogle Scholar
  • 18 Coombes R C, Kilburn L S, Snowdon C F, Paridaens R, Coleman R E, Jones S E, Jassem J, van de Velde C J, Delozier T, Alvarex I. et al . Survival and safety of exemestane versus tamoxifen after 2 - 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.  Lancet. 2007;  369 559-570
    CrossrefPubMedGoogle Scholar
  • 19 Cuzick J. Aromatase inhibitors for breast cancer prevention.  J Clin Oncol. 2005;  23 1636-1643
    CrossrefPubMedGoogle Scholar
  • 20 DeCourmelles F V. La radiotherapie indirecte ou dirigee par les correlations organiques.  Archives d'Electricite Medical. 1922;  32 264
    PubMedGoogle Scholar
  • 21 Dodds E C, Goldberg L, Lawson W, Robinson R. Oestrogenic activity of certain synthetic compounds.  Nature. 1938;  141 247-248
    PubMedGoogle Scholar
  • 22 Doisy E A, Veler C D, Thayer S. Folliculin from urine of pregnant women.  Amer J Physiol. 1929;  90 329-330
    PubMedGoogle Scholar
  • 23 Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M. et al . Letrozole, a new oral aromatase inhibitor for advanced breast cancer: a double blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.  J Clin Oncol. 1998;  16 453-461
    PubMedGoogle Scholar
  • 24 Early Breast Cancer Trialists Collaborative Group (EBCTCG) . Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.  Lancet. 1996;  347 1066-1071
    CrossrefPubMedGoogle Scholar
  • 25 Early Breast Cancer Trialists Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials.  Lancet. 2005;  365 1687-1717
    CrossrefPubMedGoogle Scholar
  • 26 Folca P J, Glascock R F, Irvine W T. Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy.  Lancet. 1961;  1 795-798
    PubMedGoogle Scholar
  • 27 Gardner W U, Strong L C, Smith G M. The mammary glands of mature female mice of strains varying in susceptibility to spontaneous tumour development.  Amer J Cancer. 1939;  37 510-517
    PubMedGoogle Scholar
  • 28 Goormaghtigh N, Amerlinck A. Realisation experimentale de la maladie de recluse de la mamelle chez la souris.  Bulletin du Cancer. 1930;  14 527-543
    PubMedGoogle Scholar
  • 29 Goss P E, Ingle J N, Martino S, Robert N J, Muss H B, Piccart M J, Castiglione M, Tu D, Shepherd L E, Pritchard K I. et al . A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer.  N Engl J Med. 2003;  349 1793-1802
    CrossrefPubMedGoogle Scholar
  • 30 Griffiths C T, Hall T C, Saba Z, Barlow J J, Nevinny H B. Preliminary trial of aminoglutethimide in breast cancer.  Cancer. 1973;  32 31-37
    CrossrefPubMedGoogle Scholar
  • 31 Haddow A, Watkinson J M, Patterson E. Influence of synthetic oestrogens upon advanced malignant disease.  British Med Journal. 1944;  2 393-398
    PubMedGoogle Scholar
  • 32 Harper M J, Walpole A L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes.  Nature. 1966;  212 87
    PubMedGoogle Scholar
  • 33 Hegar A. Die castration der Frauen. Leipzig; Breitkopf und Hartel 1878: 978
    Google Scholar
  • 34 Howell A, DeFriend D, Robertson J, Blamey R, Watson R, Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen resistant breast cancer.  Lancet. 1995;  345 29-30
    CrossrefPubMedGoogle Scholar
  • 35 Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer.  Eur Journal Cancer. 1996;  32a 576-589
    PubMedGoogle Scholar
  • 36 Howell A, Clarke R B, Anderson E. Oestrogens, Beatson and endocrine therapy.  Endocrine-Related Cancer. 1997;  4 371-380
    PubMedGoogle Scholar
  • 37 Howell A, Robertson J F, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg U R, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.  J Clin Oncol. 2002;  20 3396-3403
    CrossrefPubMedGoogle Scholar
  • 38 Howell A, Robertson J F, Abram P, Lichinitser M R, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne C K. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial.  J Clin Oncol. 2004;  22 1605-1613
    CrossrefPubMedGoogle Scholar
  • 39 Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes J F, Hoctin-Boes G, Houghton J, Locker G Y, Tobias J. ATAC Trialists Group . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer.  Lancet. 2005;  365 60-62
    CrossrefPubMedGoogle Scholar
  • 40 Howell A, Locker G Y. Defining the roles of aromatase inhibitors in the adjuvant treatment of early stage breast cancer.  Clin Breast Cancer. 2005;  6 302-309
    PubMedGoogle Scholar
  • 41 Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer.  Endocr Relat Cancer. 2006;  13 689-706
    CrossrefPubMedGoogle Scholar
  • 42 Huggins C, Dao T L. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast.  J Am Med Assoc. 1953;  151 1388-1394
    PubMedGoogle Scholar
  • 43 Huggins C. Two principles in endocrine therapy of cancers: hormone deprival and hormone interference.  Cancer Research. 1965;  25 1163-1167
    PubMedGoogle Scholar
  • 44 Iveson T J, Smith I E, Ahern I E, Smithers D A, Turnet P F, Dowsett M. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.  Cancer Res. 1993;  15 266-270
    PubMedGoogle Scholar
  • 45 Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H. et al . Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.  Lancet. 2005;  366 455-462
    CrossrefPubMedGoogle Scholar
  • 46 Jensen E V, DeSombre E R, Hurst D J, Kawashima T, Jungblut P W. Estrogen receptor interactions in target tissue.  Archives of Anatomy, Microscopy & Morphological Exp. 1967;  56 547-569
    PubMedGoogle Scholar
  • 47 Jonat W, Kaufmann M, Blamey R W, Howell A, Collins J P, Coates A, Eiermann W, Janicke F, Njordenskold B, Forbes J F. et al . A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer.  Eur J Cancer. 1995;  31 A 137-142
    CrossrefPubMedGoogle Scholar
  • 48 Jonat W, Howell A, Blomqvist C, Eiermann W, Winbald G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.  Eur J Cancer. 1996;  32a 404-412
    PubMedGoogle Scholar
  • 49 Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes J C, de Matteis A, Stewart A. et al . Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer: the Zoladex Early Breast Cancer Research Association Study.  J Clin Oncol. 2002;  20 4628-4635
    CrossrefPubMedGoogle Scholar
  • 50 Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone sensitive early stage breast cancer: a meta-analysis.  Lancet Oncol. 2006;  7 991-996
    CrossrefPubMedGoogle Scholar
  • 51 Jordan V C. Effect on tamoxifen (ICI 146,474) on initiation and growth of DMBA-induced rat mammary carcinoma.  Euro Journal of Cancer. 1976;  12 419-424
    CrossrefPubMedGoogle Scholar
  • 52 Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Janicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel H K, Schmid H. et al. . Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer.  J Clin Oncol. 1989;  7 1113-1119
    PubMedGoogle Scholar
  • 53 Kaufmann M, Jonat W, Schachner-Wunschmann E, Bastert G, Maass H. on behalf of the Cooperative German Zoladex Study Group . The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer - a 5 year experience and further endocrine therapies.  Onkologie. 1991;  14 22-30
    PubMedGoogle Scholar
  • 54 Kaufmann M, Bajetta E, Dirix L Y, Fein L E, Jones S E, Zilembo N, Dugardyn J L, Nasurdi C, Mennel R G, Cervek J. et al. . Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomised double blind trial.  J Clin Oncol. 2000;  18 1399-1411
    PubMedGoogle Scholar
  • 55 Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes J C, Schumacher M, Sauerbrei W. Zoladex Early Breast Cancer Research Association Trialists Group (ZEBRA) . Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node positive breast cancer.  Eur J Cancer. 2003;  39 1711-1717
    CrossrefPubMedGoogle Scholar
  • 56 Klijn J G, de Jong F H. Treatment with luteinising-hormone-releasing-hormone analogue (buserelin0 in premenopausal patients with metastatic breast cancer.  Lancet. 1982;  1 1213-1216
    PubMedGoogle Scholar
  • 57 Klijn J G, Beex L V, Mauriac L, van Ziji J A, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau J. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomised study.  J Natl Cancer Inst. 2000;  92 903-911
    CrossrefPubMedGoogle Scholar
  • 58 Klijn J, Blamey R W, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined Agents Trialists Group and the European Organisation for Research and Treatment of Cancer . Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials.  J Clin Oncol. 2001;  19 343-353
    PubMedGoogle Scholar
  • 59 Lacassagne A. Apparition de cancers de la mamelle chez la souris male, soumise a des injections de folliculine.  Comptes Rendus de L'Academic des Sciences Series III. 1932;  195 630-632
    PubMedGoogle Scholar
  • 60 Lacassagne A. Sur la pathologenie de l'adenocarcinoma mammaire de la souris.  Comptes Rendus de Biologie et de ses Fileiles. 1934;  115 937-939
    PubMedGoogle Scholar
  • 61 Lacassagne A. Statisque des differents cancers constates dans les lignes selectionnes de souris apres action prolongee d'hormones oestrogenes.  Assoc Français Etudes Cancer. 1938;  27 96-98
    PubMedGoogle Scholar
  • 62 Lathrop A BC, Loeb L. Further investigations on the origins of tumours in mice III. On the part played by internal secretion in the spontaneous development of tumours.  Journal of Ca Research. 1916;  1 1-19
    PubMedGoogle Scholar
  • 63 Loeb L, Blumenthal H T, Kirtz M M. The effectiveness of ovarian and hypophysial grafts in the production of mammary carcinoma in mice.  Science. 1944;  99 230-233
    CrossrefPubMedGoogle Scholar
  • 64 Lonning P E, Taylor P D, Anker G, Iddon J, Wie L, Jorgensen L M, Mella O, Howell A. High dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.  Breast Cancer Res Treat. 2001;  67 111-116
    CrossrefPubMedGoogle Scholar
  • 65 Love R R, Philips J. Oophorectomy for breast cancer: history revisited.  JNCI. 2002;  94 1433-1434
    PubMedGoogle Scholar
  • 66 Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom H P, Janicke F. et al . Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a phase II study of the International Letrozole Breast Cancer Group.  J Clin Oncol. 2001;  19 2596-2606
    PubMedGoogle Scholar
  • 67 Nunn T W. On cancer of the breast. London; J & A Churchill 1882: 71
    Google Scholar
  • 68 Osborne C K, Coronado-Heinsohn E B, Hilsenbeck S G, McCue B L, Wakeling A E, McClelland R A, Manning D L, Nicholson R I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.  J Natl Cancer Inst. 1995;  87 746-750
    PubMedGoogle Scholar
  • 69 Osborne C K, Pippen J, Jones S E, Parker L M, Ellis M, Come S, Gertier S Z, May J T, Burton G, Dimery I. et al . Double blind randomised trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.  J Clin Oncol. 2002;  20 3386-3395
    CrossrefPubMedGoogle Scholar
  • 70 Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A. et al . Mature results of a randomised phase II multicenter study of exemestane versus tamoxifen as first line hormone therapy for postmenopausal women with metastatic breast cancer.  Ann Oncol. 2003;  14 1391-1398
    CrossrefPubMedGoogle Scholar
  • 71 Paterson R. Breast cancer. A report of two clinical trials.  J R Coll Surg. 1962;  7 243-254
    PubMedGoogle Scholar
  • 72 Peethambaram P P, Ingle J N, Suman V J, Hartmann L C, Loprinzi C L. Randomised trial of diethylstilbestrol v tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.  Breast cancer Res Treat. 1999;  54 117-122
    CrossrefPubMedGoogle Scholar
  • 73 Pyrhonen S, Ellmen J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes D F. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.  Breast Cancer Res Treat. 1999;  56 133-143
    PubMedGoogle Scholar
  • 74 Rody A, Loibl S, von Minckwitz G, Kaufmann M. Use of goserelin in the treatment of breast cancer.  Expert Rev Anticancer Ther. 2005;  5 591-604
    CrossrefPubMedGoogle Scholar
  • 75 Schinzinger A, Maxfield W S. Ueber carcinoma mammae.  Zent Org Gesamle Chir. 1889;  29 55-57
    PubMedGoogle Scholar
  • 76 Schinzinger A. Ueber carcinoma mammae (abstract). 18th Congress of the German Society for Surgery.  Beilage zum Centralblatt fur Chirurgie. 1889;  16 55-56
    PubMedGoogle Scholar
  • 78 Schinzinger A. Ueber carcinoma mammae (abstract). Verhandlungen der Deutschen Gesellschaft fur Chirurgie. 18th Congress, Berlin 24 - 27 April 1889. 1889: 28
    Google Scholar
  • 79 Ulrich P. Testosterone et son role possible dans le traitment de certains cancers du sein.  Union Against Cancer. 1939;  4 377
    PubMedGoogle Scholar
  • 80 Wakeling A E, Bowler J. ICI 182, 780, a new antioestrogen with clinical potential.  J Steroid Biochem Mol Biol. 1992;  43 173-177
    CrossrefPubMedGoogle Scholar
  • 81 Walker K J, Nicholson R I, Turkes A O, Turkes A, Griffiths K, Robinson M, Crispin Z, Dris S. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.  Lancet. 1983;  2 413-415
    PubMedGoogle Scholar
  • 82 Walpole A L, Patterson E. Synthetic oestrogens in mammary cancer.  Lancet. 1949;  2 783-786
    PubMedGoogle Scholar
  • 83 Wells Jr S A, Worgul T J, Samojilik E, Boucher A E, Lipton A, Harvey H, White D, Smart E, Cox C, Santen R J. Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.  Cancer Res. 1982;  42 3454s-3457s
    PubMedGoogle Scholar
  • 84 Williams M R, Walker K J, Turkes A, Blamey R W, Nicholson R I. The use of an LHRH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.  Br J Cancer. 1986;  53 629-636
    PubMedGoogle Scholar
  • 85 Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefice S, Buzzoni R, Di Bartolomeo M, Di Leo A, Laffranchi A. et al . Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.  Br J Cancer. 1995;  72 1007-1012
    PubMedGoogle Scholar
  • 86 DeFriend D, Howell A, Nicholson R I, Anderson E, Dowsett M, Mansel R E, Blamey R W, Bundred N J, Robertson J F, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling A E. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.  Cancer Research. 1994;  54 408-414
    PubMedGoogle Scholar
  • 87 Gradishar W J, Cella D. Selective estrogen receptor modulators and prevention of invasive breast cancer.  JAMA. 2006;  295 2784-2786
    CrossrefPubMedGoogle Scholar

Anthony Howell

CRUK Department of Medical Oncology
University of Manchester

Manchester, M20 4BX

United Kingdom

Email: maria.parker@christie.nhs.uk